Reduced intensity conditioning with Fludarabine, BCNU and Melphalan (FBM) for allogeneic hematopoietic cell transplantation in elderly AML patients: remission status at transplant predicts outcome

被引：0
|
作者：
Wais, V. [1 ]
Kuendgen, L. [2 ]
Bohl, S. [1 ]
von Harsdorf, S. [1 ]
Schlenk, R. F. [1 ]
Doehner, K. [1 ]
Teleanu, V. [1 ]
Bullinger, L. [1 ]
Drognitz, K. [2 ]
Moulin, J. -C. [2 ]
Binnenhei, M. [2 ]
Bentz, M. [2 ]
Doehner, H. [1 ]
Bunjes, D. [1 ]
Ringhoffer, M. [2 ]
Kuchenbauer, F. [1 ]
机构：
[1] Univ Hosp Ulm, Ulm, Germany
[2] Municipal Hosp Karlsruhe, Karlsruhe, Germany
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P616
引用
收藏
页码：S442 / S443
页数：2
相关论文
共 50 条
  • [1] Reduced Intensity Conditioning with Fludarabine, BCNU and Melphalan (FBM) for Allogeneic Hematopoietic Cell Transplantation in Elderly AML Patients: Factors Predicting Outcome
    Wais, Verena
    Bohl, Stephan
    Kuendgen, Lukas
    von Harsdorf, Stephanie
    Scholl, Katrina
    Schlenk, Richard F.
    Hofmann, Susanne
    Maier, C. Philipp
    Doehner, Konstanze
    Teleanu, Maria-Veronica
    Bullinger, Lars
    Drognitz, Kathrin
    Moulin, Jean-Charles
    Binnenhei, Martin
    Bentz, Martin
    Doehner, Hartmut
    Bunjes, Donald
    Ringhoffer, Mark
    Kuchenbauer, Florian
    BLOOD, 2015, 126 (23)
  • [2] Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome
    Wais, V.
    Kuendgen, L.
    Bohl, S. R.
    von Harsdorf, S.
    Schlenk, R. F.
    Doehner, K.
    Teleanu, V.
    Bullinger, L.
    Nguyen, T. M.
    Drognitz, K.
    Moulin, J-C
    Binnenhei, M.
    Bentz, M.
    Doehner, H.
    Bunjes, D.
    Kuchenbauer, F.
    Ringhoffer, M.
    BONE MARROW TRANSPLANTATION, 2018, 53 (01) : 94 - 96
  • [3] Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome
    V Wais
    L Kündgen
    S R Bohl
    S von Harsdorf
    R F Schlenk
    K Döhner
    V Teleanu
    L Bullinger
    T M Nguyen
    K Drognitz
    J-C Moulin
    M Binnenhei
    M Bentz
    H Döhner
    D Bunjes
    F Kuchenbauer
    M Ringhoffer
    Bone Marrow Transplantation, 2018, 53 : 94 - 96
  • [4] Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with Flamsa-Busulfan Versus Fludarabine/BCNU/Melphalan
    Engel, Nicole
    Hill, Wolfgang
    Fritsch, Susanne
    Prevalsek, Dusan
    Zoellner, Anna-Katharina
    Hubmann, Max
    Buecklein, Veit
    Hausmann, Andreas
    Ledderose, Georg
    Kolb, Hans-Jochem
    Hiddemann, Wolfgang
    Tischer, Johanna
    BLOOD, 2014, 124 (21)
  • [5] Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with FLAMSA-Busulfan versus Fludarabine/BCNU/Melphalan
    Fritsch, S.
    Engel, N.
    Hill, W.
    Prevalsek, D.
    Zoellner, A.
    Hubmann, M.
    Buecklein, V.
    Hausmann, A.
    Ledderose, G.
    Kolb, H-J
    Schmid, C.
    Hiddemann, W.
    Tischer, I.
    BONE MARROW TRANSPLANTATION, 2015, 50 : S480 - S481
  • [6] Comparison of fludarabine/melphalan(flumel) with fludarabine/melphalan/bcnu or thiotepa(fbm/ftm) in patients with AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the ebmt alwp
    Duque-Afonso, J.
    Finke, J.
    Ngoya, M.
    Labopin, M.
    Nicholson, E.
    Kottaridis, P.
    Craddock, C.
    Tholouli, E.
    Protheroe, R.
    Wagner-Drouet, E. M.
    Bloor, A.
    Valerius, T.
    Wilson, K. M. O.
    Savani, B. N.
    Spyridonidis, A.
    Nagler, A.
    Mohty, M.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 164 - 165
  • [7] Fludarabine/melphalan conditioning for allogeneic stem cell transplantation (SCT) in elderly patients with AML/MDS
    Kennedy, GA
    Butler, J
    Durrant, S
    Hill, GR
    Western, R
    Morton, J
    BLOOD, 2005, 106 (11) : 438B - 439B
  • [8] Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party
    Afonso, Jesus Duque
    Finke, Juergen
    Ngoya, Maud
    Galimard, Jacques-Emmanuel
    Craddock, Charles
    Raj, Kavita
    Bloor, Adrian
    Nicholson, Emma
    Eder, Matthias
    Orchard, Kim H.
    Valerius, Thomas
    Snowden, John A.
    Tholouli, Eleni
    Crawley, Charles
    Collin, Matthew P.
    Wilson, Keith
    Gadisseur, Alain
    Protheroe, Rachel Elizabeth
    Wagner, Eva Maria
    Savani, Bipin
    Spyridonidis, Alexandros
    Ciceri, Fabio
    Nagler, Arnon
    Mohty, Mohamad
    BLOOD, 2022, 140 : 2110 - 2112
  • [9] Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party
    Duque-Afonso, Jesus
    Finke, Juergen
    Ngoya, Maud
    Galimard, Jacques-Emmanuel
    Craddock, Charles
    Raj, Kavita
    Bloor, Adrian
    Nicholson, Emma
    Eder, Matthias
    Kim, Orchard
    Valerius, Thomas
    Snowden, John A.
    Tholouli, Eleni
    Crawley, Charles
    Collin, Matthew
    Wilson, Keith M. O.
    Gadisseur, Alain
    Protheroe, Rachel
    Wagner-Drouet, Eva Maria
    Savani, Bipin N.
    Spyridonidis, Alexandros
    Ciceri, Fabio
    Nagler, Arnon
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2024, 59 (02) : 247 - 254
  • [10] Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party
    Jesús Duque-Afonso
    Jürgen Finke
    Maud Ngoya
    Jacques-Emmanuel Galimard
    Charles Craddock
    Kavita Raj
    Adrian Bloor
    Emma Nicholson
    Matthias Eder
    Orchard Kim
    Thomas Valerius
    John A. Snowden
    Eleni Tholouli
    Charles Crawley
    Matthew Collin
    Keith M. O. Wilson
    Alain Gadisseur
    Rachel Protheroe
    Eva Maria Wagner-Drouet
    Bipin N. Savani
    Alexandros Spyridonidis
    Fabio Ciceri
    Arnon Nagler
    Mohamad Mohty
    Bone Marrow Transplantation, 2024, 59 : 247 - 254
12345